Citations

Clear

4207 citation(s) found for "Yu, Chen".

Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure
Smith, Sonali M. , Godfrey, James , Ahn, Kwang Woo , Digilio, Alessandro, Ahmed, Sairah , Bachanová, Veronika , Bashey, Asad, Bolaños‐Meade, Javier , Cairo, Mitchell S. , Chen, Andy , Copelan, Edward A. , Aljurf, Mahmoud , Farooq, Umar , Ganguly, Siddhartha , Holmberg, Leona , Inwards, David J. , Kanate, Abraham S. , Karmali, Reem , Kenkre, Vaishalee P. , Kharfan‐Dabaja, Mohamed A. , Klein, Andreas K. , Mei, Matthew , Geethakumari, Praveen Ramakrishnan , Saad, Ayman , Schouten, Harry C. , Shah, Nirav N. , Urbano-Ispizúa, Álvaro , Vij, Ravi , Sureda, Anna , Holmberg, Leona , Bachanova, Veronika , Inwards, David, Mussetti, Alberto , Savani, Bipin N , Sureda, Anna , Hamadani, Mehdi , Chen, Andy I. , Saad, Ayman , Mei, Matthew , Farooq, Umar , Ahmed, Sairah , Karmali, Reem , Agrawal, Vaibhav , Bacher, Ulrike , Chhabra, Saurabh , Dahi, Parastoo B , Hertzberg, Mark , Lazarus, Hillard M. , Mussetti, Alberto , Nishihori, Taiga , Savani, Bipin N. , Vose, Julie M. , Hamadani, Mehdi

Mayo Clinic

Cancer | April 12, 2018 | Volume: 124 | Issue: 12 | Pages: 2541-2551

10.1002/cncr.31374 | PMID 29645093 Get It

BACKGROUNDEarly treatment failure (ETF) in follicular lymphoma (FL), defined as relapse or progression within 2 years of frontline chemoimmunotherapy, is a newly recognized marker of poor survival and identifies a high‐risk group of patients with an expected 5‐year overall survival (OS) rate of approximately 50%. Transplantation is an established option for relapsed FL, but its efficacy in this specific ETF FL population has not been previously evaluated.METHODSThis study compared autologous hematopoietic stem cell transplantation (auto‐HCT) with either matched sibling donor (MSD) or matched unrelated donor (MUD) allogeneic hematopoietic cell transplantation (allo‐HCT) as the first transplantation approach for patients with ETF FL (age ≥ 18 years) undergoing auto‐HCT or allo‐HCT between 2002 and 2014. The primary endpoint was OS. The secondary endpoints were progression‐free survival, relapse, and nonrelapse mortality (NRM).RESULTSFour hundred forty FL patients had ETF (auto‐HCT, 240; MSD hematopoietic stem cell transplantation [HCT], 105; and MUD HCT, 95). With a median follow‐up of 69 to 73 months, the adjusted probability of 5‐year OS was significantly higher after auto‐HCT (70%) or MSD HCT (73%) versus MUD HCT (49%; P = .0008). The 5‐year adjusted probability of NRM was significantly lower for auto‐HCT (5%) versus MSD (17%) or MUD HCT (33%; P < .0001). The 5‐year adjusted probability of disease relapse was lower with MSD (31%) or MUD HCT (23%) versus auto‐HCT (58%; P < .0001).CONCLUSIONSPatients with high‐risk FL, as defined by ETF, undergoing auto‐HCT for FL have low NRM and a promising 5‐year OS rate (70%). MSD HCT has lower relapse rates than auto‐HCT but similar OS. Cancer 2018;124:2541‐51. © 2018 American Cancer Society.
The State of US Health, 1990-2016
Collaborators, The US Burden of Disease, Mokdad, Ali H. , Ballestros, Katherine, Echko, Michelle, Glenn, Scott , Olsen, Helen Elizabeth , Mullany, Erin C, Lee, Alex , Khan, Abdur Rahman , Ahmadi, Alireza , Ferrari, Alize J , Kasaeian, Amir , Werdecker, Andrea , Carter, Austin , Zipkin, Ben, Sartorius, Benn , Serdar, Berrin , Sykes, Bryan L. , Troeger, Chris, Fitzmaurice, Christina , Rehm, Colin D. , Santomauro, Damian , Kim, Daniel , Colombara, Danny V. , Schwebel, David C. , Tsoi, Derrick, Nichols, Emma , Oren, Eyal , Charlson, Fiona , Patton, George , Roth, Gregory A. , Kyu, Hmwe Hmwe , Erskine, Holly E , Huang, Hsiang , Martopullo, Ira , Nachega, Jean B. , Sanabria, Juan , Tabb, Karen M. , Krohn, Kristopher J, Cornaby, Leslie, Moses, Mark , Farvid, Maryam S. , Griswold, Max , Criqui, Michael H, Bell, Michelle L. , Nguyen, Minh , Wallin, Mitch, Mirarefin, Mojde, Younis, Mustafa Z , Fullman, Nancy , Liu, Patrick , Briant, Paul Svitil, Gona, Philimon , Havmöller, Rasmus, Kimokoti, Ruth W , Hay, Simon I , Yadgir, Simon , Biryukov, Stan, Vollset, Stein Emil, Alam, Shazia , Frank, Tahvi , Farid, Talha, Miller, Ted R. , Vos, Theo , Bärnighausen, Till , Gebrehiwot, Tsegaye, Yano, Yuichiro , Al‐Aly, Ziyad , Mehari, Alem , Handal, Alexis J. , Kandel, Amit , Anderson, Benjamin O. , Biroscak, Brian J. , Dorsey, E. Ray, Ding, Eric L. , Park, Eun‐Kee , Wagner, Gregory R. , Chen, Honglei , Sunshine, Jacob E. , Khubchandani, Jagdish , Leasher, Janet L , Leung, Janni , Unützer, Jürgen , Cahill, Leah E. , Cooper, Leslie T. , Bräuer, Michael , Breitborde, Nicholas J. K. , Topór-Mądry, Roman , Soneji, Samir , Stranges, Saverio , James, Spencer L , Amrock, Stephen M. , Jayaraman, Sudha , Skirbekk, Vegard , Kinfu, Yohannes , Bhutta, Zulfiqar A , Murray, Christopher J L , Topór‐Mądry, Roman , Bell, Max , Cooper, Leslie T , Collaborators, The US Burden of Disease, Kolte, Dhaval , Nsoesie, Elaine Okanyene , Hosgood, H. Dean, Whiteford, Harvey , Singh, Jasvinder A. , Abbas, Kaja , Ong, Sok King , Degenhardt, Louisa J , Qorbani, Mostafa , Leung, Ricky , Bazargan‐Hejazi, Shahrzad , Vollset, Stein Emil, Mozaffarian, Dariush , Hu, Guoqing , Salomon, Joshua A. , Horino, Masako , Hotez, Peter Jay , Patel, Tejas Kamleshbhai , Akinyemiju, Tomi , Jonas, Jost B , Oren, Eyal

Mayo Clinic

JAMA | April 10, 2018 | Volume: 319 | Issue: 14 | Pages: 1444

10.1001/jama.2018.0158 | PMID 29634829 Get It

Relationship between Hospital 30‐Day Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care
Chen, Lena M. , Levine, Deborah A. , Hayward, Rodney A. , Cox, Margueritte, Schulte, Phillip J. , Heidenreich, Paul A. , DeVore, Adam D. , Hernandez, Adrian F. , Yancy, Clyde W. , Fonarow, Gregg C.

Mayo Clinic

Journal of Hospital Medicine | April 6, 2018 | Volume: 13 | Issue: 3 | Pages: 170-176

10.12788/jhm.2862 | PMID 29505624 Get It

BACKGROUNDThe Centers for Medicare & Medicaid Services rewards hospitals that have low 30‐day risk‐standardized mortality rates (RSMR) for heart failure (HF).OBJECTIVETo describe the use of early comfort care for patients with HF, and whether hospitals that more commonly initiate comfort care have higher 30‐day mortality rates.DESIGNA retrospective, observational study.SETTINGAcute care hospitals in the United States.PATIENTSA total of 93,920 fee‐for‐service Medicare beneficiaries admitted with HF from January 2008 to December 2014 to 272 hospitals participating in the Get With The Guidelines‐Heart Failure registry.EXPOSUREEarly comfort care (defined as comfort care within 48 hours of hospitalization) rate.MEASUREMENTSA 30‐day RSMR.RESULTSHospitals' early comfort care rates were low for patients admitted for H F, with no change over time (2.5% to 2.6%, from 2008 to 2014, P = .56). Rates varied widely (0% to 40%), with 14.3% of hospitals not initiating comfort care for any patients during the first 2 days of hospitalization. Risk‐standardized early comfort care rates were not correlated with RSMR (median RSMR = 10.9%, 25th to 75th percentile = 10.1% to 12.0%; Spearman's rank correlation = 0.13; P = .66).CONCLUSIONSHospital use of early comfort care for HF varies, has not increased over time, and on average, is not correlated with 30‐day RSMR. This suggests that current efforts to lower mortality rates have not had unintended consequences for hospitals that institute early comfort care more commonly than their peers.
Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET
Stonnington, Cynthia M. , Chen, Yinghua , Savage, Cary R. , Lee, Wendy , Bauer, Robert, Sharieff, Sameen, Alexander, Gene E. , Caselli, Richard J. , Reiman, Eric M. , Locke, Dona E.C. , Thiyyagura, Pradeep , Chen, Kewei

Mayo Clinic

Journal of Alzheimer’s Disease | April 6, 2018 | Volume: 63 | Issue: 2 | Pages: 603-615

10.3233/jad-170852 | PMID 29630550 Get It

Background: Brain imaging measurements can provide evidence of possible preclinical Alzheimer’s disease (AD). Their ability to predict individual imminent clinical conversion remains unclear. Objective: To investigate the ability of pre-specified volumetric magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography (FDG-PET) measurements to predict which cognitively unimpaired older participants would subsequently progress to amnestic mild cognitive impairment (aMCI) within 2 years. Methods: From an apolipoprotein E4 (APOE4) enriched prospective cohort study, 18 participants subsequently progressed to the clinical diagnosis of aMCI or probable AD dementia within 1.8±0.8 years (progressors); 20 participants matched for sex, age, education, and APOE allele dose remained cognitively unimpaired for at least 4 years (nonprogressors). A complementary control group not matched for APOE allele dose included 35 nonprogressors. Groups were compared on baseline FDG-PET and MRI measures known to be preferentially affected in the preclinical and clinical stages of AD and by voxel-wise differences in regional gray matter volume and glucose metabolism. Receiver Operating Characteristic, binary logistic regression, and leave-one-out procedures were used to predict clinical outcome for the a priori measures. Results: Compared to non-progressors and regardless of APOE-matching, progressors had significantly reduced baseline MRI and PET measurements in brain regions preferentially affected by AD and reduced hippocampal volume was the strongest predictor of an individual’s imminent progression to clinically significant memory decline (79% sensitivity/78% specificity among APOE-matched cohorts). Conclusion: Regional MRI and FDG-PET measurements may be useful in predicting imminent progression to clinically significant memory decline.
Expression of the B splice variant of NBCe1 (SLC4A4) in the mouse kidney
Fang, Lijuan, Lee, Hyun‐Wook , Chen, Chao , Harris, Autumn N. , Romero, Michael F. , Verlander, Jill W. , Weiner, I. David , Weiner, I David , Romero, Michael F

Mayo Clinic

American Journal of Physiology-Renal Physiology | April 4, 2018 | Volume: 315 | Issue: 3 | Pages: F417-F428

10.1152/ajprenal.00515.2017 | PMID 29631353 Get It

Sodium-coupled bicarbonate transporters are critical for renal electrolyte transport. The electrogenic, sodium-coupled bicarbonate cotransporter, isoform 1 (NBCe1), encoded by the SLC4A4 geneencoded by the SLC4A4 gene has five multiple splice variants; the A splice variant, NBCe1-A, is the primary basolateral bicarbonate transporter in the proximal convoluted tubule. This study’s purpose was to determine if there is expression of additional NBCe1 splice variants in the mouse kidney, their cellular distribution, and their regulation by metabolic acidosis. In wild-type mice, an antibody reactive only to NBCe1-A showed basolateral immunolabel only in cortical proximal tubule (PT) segments, whereas an antibody reactive to all NBCe1 splice variants (pan-NBCe1) showed basolateral immunolabel in PT segments in both the cortex and outer medulla. In mice with NBCe1-A deletion, the pan-NBCe1 antibody showed basolateral PT immunolabel in both the renal cortex and outer stripe of the outer medulla, and immunoblot analysis showed expression of a ~121-kDa protein. RT-PCR of mRNA from NBCe1-A knockout mice directed at splice variant-specific regions showed expression of only NBCe1-B mRNA. In wild-type kidney, RT-PCR confirmed expression of mRNA for the NBCe1-B splice variant and absence of mRNA for the C, D, and E splice variants. Finally, exogenous acid loading increased expression in the proximal straight tubule in the outer stripe of the outer medulla. These studies demonstrate that the NBCe1-B splice variant is present in the PT, and its expression increases in response to exogenous acid loading, suggesting it participates in the PT contribution to acid-base homeostasis.
GMPR: A robust normalization method for zero-inflated count data with application to microbiome sequencing data
Chen, Li , Reeve, James , Zhang, L. , Huang, Shengbing, Wang, Xuefeng , Chen, Jun

Mayo Clinic

PeerJ | April 2, 2018 | Volume: 6 | Issue: No issue available | Pages: e4600

10.7717/peerj.4600 | PMID 29629248 Get It

Normalization is the first critical step in microbiome sequencing data analysis used to account for variable library sizes. Current RNA-Seq based normalization methods that have been adapted for microbiome data fail to consider the unique characteristics of microbiome data, which contain a vast number of zeros due to the physical absence or under-sampling of the microbes. Normalization methods that specifically address the zero-inflation remain largely undeveloped. Here we propose geometric mean of pairwise ratios—a simple but effective normalization method—for zero-inflated sequencing data such as microbiome data. Simulation studies and real datasets analyses demonstrate that the proposed method is more robust than competing methods, leading to more powerful detection of differentially abundant taxa and higher reproducibility of the relative abundances of taxa.
Olfactory function and neurocognitive outcomes in old age: The Atherosclerosis Risk in Communities Neurocognitive Study
Palta, Priya, Chen, Honglei , Sharrett, A. Richey, Gross, Alden L. , Griswold, Michael , Heiss, Gerardo , Deal, Jennifer A. , Knopman, David S. , Mosley, Thomas H.

Mayo Clinic

Alzheimer's & Dementia | March 30, 2018 | Volume: 14 | Issue: 8 | Pages: 1015-1021

10.1016/j.jalz.2018.02.019 | PMID 29605223 Get It

AbstractIntroductionWe tested the hypothesis that poor sense of smell is associated with lower cognitive function and higher mild cognitive impairment (MCI) prevalence.MethodsOlfaction, measured by the Sniffin' Sticks test, was categorized as olfactory impairment (OI) (score ≤6) or no OI (score >6). MCI was adjudicated based on review of a neuropsychological examination. Linear regression estimated the mean difference in cognitive factor scores, and log‐binomial regression quantified MCI prevalence among participants with versus without OI.ResultsParticipants with OI had lower mean factor scores (memory: −0.27 standard deviation [SD], 95% confidence interval [CI]: −0.35 to −0.19; language: −0.24 SD, 95% CI: −0.30 to −0.17; executive function/processing speed: −0.09 SD, 95% CI: −0.12 to −0.06; and general cognitive performance: −0.25 SD, 95% CI: −0.30 to −0.20). OI was also associated with MCI (n = 204; prevalence ratio = 1.56, 95% CI: 1.37, 1.78).DiscussionAn impaired sense of smell may serve as a readily accessible early marker of neurodegeneration and improve upon the prevailing delayed diagnoses and underascertainment of MCI/dementia.
Developing drugs for treatment of atopic dermatitis in children (≥3 months to
Siegfried, Elaine C. , Jaworski, Jennifer C., Eichenfield, Lawrence F. , Altman, Emily , Arena, Charles, Block, Julie, Boguniewicz, Mark , Chen, Suephy C. , Hanna, Diane , Horii, Kimberly A., Hultsch, Thomas , Lio, Peter , Milner, Joshua D. , Omachi, Theodore A. , Schneider, Lynda C. , Sidbury, Robert , Smith, Timothy W. , Sugarman, Jeffrey, Taha, Sharif, Tofte, Susan, Tollefson, Megha M. , Tom, Wynnis L. , Whitney, Lucinda , Zane, Lee T., Tollefson, Megha, Paller, Amy S. , Hebert, Adelaide Ann , Simpson, Eric Lawrence , Blauvelt, Andrew , Cordoro, Kelly M. , Lee, James , Leung, Donald Y.M. , Schneider, Christine B. , Sugarman, Jeffrey, West, Dennis Paul

Mayo Clinic

Pediatric Dermatology | March 30, 2018 | Volume: 35 | Issue: 3 | Pages: 303-322

10.1111/pde.13452 | PMID 29600515 Get It

AbstractAtopic dermatitis is the most common chronic skin disease, and it primarily affects children. Although atopic dermatitis (AD) has the highest effect on burden of skin disease, no high‐level studies have defined optimal therapy for severe disease. Corticosteroids have been used to treat AD since the 1950s and remain the only systemic medication with Food and Drug Administration approval for this indication in children, despite published guidelines of care that recommend against this option. Several clinical trials with level 1 evidence have supported the use of topical treatments for mild to moderate atopic dermatitis in adults and children, but these trials have had little consistency in protocol design. Consensus recommendations will help standardize clinical development and trial design for children. The Food and Drug Administration issues guidance documents for industry as a source for “the Agency's current thinking on a particular subject.” Although they are nonbinding, industry considers these documents to be the standard for clinical development and trial design. Our consensus group is the first to specifically address clinical trial design in this population. We developed a draft guidance document for industry, Developing Drugs for Treatment of Atopic Dermatitis in Children (≥3 months to <18 years of age). This draft guidance has been submitted to the Food and Drug Administration based on a provision in the Federal Register (Good Guidance Practices).
Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications
Chen, Yang , Burnett, John C.

Mayo Clinic

International Journal of Molecular Sciences | March 27, 2018 | Volume: 19 | Issue: 4 | Pages: 1006

10.3390/ijms19041006 | PMID 29584705 Get It

The particulate guanylyl cyclase A (pGC-A)/cGMP pathway plays important roles in regulating renal physiological function and as well as in counteracting pathophysiological conditions. Naturally occurring peptide pGC-A activators consist of atrial natriuretic peptide (ANP), b-type NP (BNP), and urodilatin (URO). These activators bind and activate pGC-A, generating the second messenger cyclic 3′,5′ guanosine monophosphate (cGMP). Cyclic GMP binds to downstream pathway effector molecules including protein kinase G (PKG), cGMP-gated ion channels, and phosphodiesterases (PDEs). These mediators result in a variety of physiological actions in the kidney, including diuresis, natriuresis, increased glomerular filtration rate (GFR) and organ protection, thus, opposing renal cellular injury and remodeling. Downstream proteins regulated by PKG include collagen 1 (Col-1), transforming growth factor beta (TGF-β) and apoptosis-related proteins. In addition to their physiological regulatory effects, pGC-A/cGMP signaling is critical for preserving renal homeostasis in different renal diseases such as acute kidney injury (AKI). Regarding therapeutic options, native pGC-A activators have short half-lives and their activity can be further enhanced by advances in innovative peptide engineering. Thus, novel designer peptide pGC-A activators with enhanced renal activity are under development.
Microtubule associated tumor suppressor 1 interacts with mitofusins to regulate mitochondrial morphology in endothelial cells
Wang, Yinfang, Liu, Youbin , Li, Jin‐Ping , Hao, Yilong, Yin, Peihao , Liu, Zongjun , Chen, Jingzhou , Wang, Ying , Wang, Nanping , Zhang, Peng , Wang, Yinfang, Huang, Yitong Pepper , Wang, Ying

Mayo Clinic

The FASEB Journal | March 20, 2018 | Volume: 32 | Issue: 8 | Pages: 4504-4518

10.1096/fj.201701143rr | PMID 29558204 Get It

Mitochondria are dynamic organelles that are able to change their morphology and cellular distribution by either fission or fusion. However, the molecular mechanisms controlling mitochondrial dynamics in vascular endothelial cells (ECs) remain largely unknown. In this study, we observed that knockdown of microtubule‐associated tumor suppressor 1 (MTUS1) in ECs inhibited tube formation and migration, accompanied with decreased promigratory signalings. We showed that MTUS1 was localized in the outer membrane of mitochondria in ECs. Knockdown of MTUS1 disturbed the elongated mitochondrial network and induced the formation of perinuclear clusters of mitochondria. Importantly, mitochondrial motility and fusion were suppressed, whereas generation of reactive oxygen species was increased in MTUS1 knockdown ECs. Mechanistically, we showed that the N‐terminal coiled‐coil domain of MTUS1 interacted with the mitochondrial membrane proteins, mitofusin‐1 and mitofusin‐2, to maintain mitochondrial morphology in ECs. This study illustrated a novel role of MTUS1 in mitochondrial morphology and EC angiogenic responses.—Wang Y., Huang Y., Liu, Y., Li, J., Hao, Y., Yin, P., Liu, Z., Chen J., Wang Y., Wang N., Zhang P., Microtubule associated tumor suppressor 1 interacts with mitofusins to regulate mitochondrial morphology in endothelial cells. FASEB J . 32, 4504–4518 (2018). www.fasebj.org